GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Net Income

Serina Therapeutics (Serina Therapeutics) Net Income : $-8.63 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Serina Therapeutics's Net Income for the six months ended in Mar. 2024 was $-9.44 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.63 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Serina Therapeutics's Earnings per Share (Diluted) for the six months ended in Mar. 2024 was $-1.10.


Serina Therapeutics Net Income Historical Data

The historical data trend for Serina Therapeutics's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Net Income Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22
Net Income
-1.27 -2.68

Serina Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Mar24
Net Income - -1.41 -1.27 0.81 -9.44

Serina Therapeutics Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Serina Therapeutics's Net Income for the fiscal year that ended in Dec. 2022 is calculated as

Net Income(A: Dec. 2022 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-2.682+0+0+0
=-2.68

Serina Therapeutics's Net Income for the quarter that ended in Mar. 2024 is calculated as

Net Income(Q: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-9.437+0+0+0
=-9.44

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-8.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Serina Therapeutics  (AMEX:SER) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Serina Therapeutics's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Serina Therapeutics Net Income Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Serina Therapeutics (Serina Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines